^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    trastuzumab rezetecan (SHR-A1811)

    i
    Other names: SHR-A1811, SHRA1811, SHR A1811, SHR-1811, SHR1811, SHR 1811
    Company:
    Glenmark, Jiangsu Hengrui Pharma
    Drug class:
    Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate
    Related drugs:
    9d
    A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing (clinicaltrials.gov)
    P2, N=88, Active, not recruiting, Fudan University | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • AR (Androgen receptor)
    |
    HER-2 positive • HER-2 amplification • HER-2 mutation • AR positive
    |
    trastuzumab rezetecan (SHR-A1811) • leuprolide acetate for depot suspension • AiRuiEn (rezvilutamide) • tizetatug rezetecan (SHR-A1921)
    13d
    MA-UC-II-007: Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) (clinicaltrials.gov)
    P2, N=96, Recruiting, Sun Yat-sen University
    New P2 trial
    |
    Herceptin (trastuzumab) • carboplatin • trastuzumab rezetecan (SHR-A1811) • AiRuiLi (adebrelimab)
    17d
    A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer (clinicaltrials.gov)
    P2, N=60, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    trastuzumab rezetecan (SHR-A1811)
    18d
    A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer (clinicaltrials.gov)
    P3, N=650, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab) • trastuzumab rezetecan (SHR-A1811)
    1m
    A Multicenter, Open-Label Phase II Clinical Study Evaluating the Safety, Tolerability, and Efficacy of SHR2554 Tablets in Combination with Other Antitumor Therapies in Patients with Locally Advanced Unresectable or Metastatic Gastric or Gastro-oesophageal Junction Adenocarcinoma (ChiCTR2500110933)
    P2, N=366, Recruiting, Harbin Medical University Cancer Hospital; Harbin Medical University Cancer Hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18)
    |
    PD-L1 expression • HER-2 expression
    |
    trastuzumab rezetecan (SHR-A1811) • retlirafusp alfa (SHR-1701) • zeprumetostat (SHR-2554) • AiRuiLi (adebrelimab) • garetatug rezetecan (SHR-A1904)
    1m
    A Phase II Clinical Study of Trastuzumab Rezetecan (SHR-A1811) or in Combination With Adebrelimab (SHR-1316) for HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) (ChiCTR2500110227)
    P2, N=96, Recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 expression
    |
    Herceptin (trastuzumab) • trastuzumab rezetecan (SHR-A1811) • AiRuiLi (adebrelimab)
    1m
    Single arm, multicenter, exploratory phase II clinical study of new adjuvant therapy with Trastuzumab Deruxtecan for Injection for injection for early or locally advanced HR positive/HER2 low expression breast cancer with poor efficacy of dalpiciclib combined with endocrine therapy (ChiCTR2500110276)
    P4, N=30, Not yet recruiting, Anyang Tumor Hospital; Anyang Tumor Hospital
    New P4 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 expression • HER-2 underexpression
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • letrozole • trastuzumab rezetecan (SHR-A1811) • AiRuiKang (dalpiciclib)
    1m
    Phase I/II clinical study of SHR-A1811 combined regimen for injection in treatment of platinum-sensitive recurrent ovarian cancer (ChiCTR2500109601)
    P1/2, N=42, Recruiting, Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College ,Huazhong University o
    New P1/2 trial • Platinum sensitive
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    HER-2 expression • HRD
    |
    Avastin (bevacizumab) • trastuzumab rezetecan (SHR-A1811)
    1m
    A prospective clinical study of SHR-A1811 monotherapy or combined with pertuzumab in the treatment of HER2-positive advanced breast cancer with brain metastases after progression with pyrotinib (ChiCTR2500108436)
    P4, N=40, Not yet recruiting, Changde First People's Hospital; Changde First People's Hospital
    New P4 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 expression
    |
    Perjeta (pertuzumab) • Irene (pyrotinib) • trastuzumab rezetecan (SHR-A1811)
    2ms
    The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis (clinicaltrials.gov)
    P2, N=184, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P2 trial
    |
    Herceptin (trastuzumab) • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate) • trastuzumab rezetecan (SHR-A1811)
    2ms
    A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=150, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | N=50 --> 150
    Enrollment change • Platinum sensitive
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • oxaliplatin • trastuzumab rezetecan (SHR-A1811) • AiRuiLi (adebrelimab)
    2ms
    A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer (clinicaltrials.gov)
    P3, N=650, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P3 trial
    |
    Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab) • trastuzumab rezetecan (SHR-A1811)